Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346744 | 0.84 | OPRK1 (0.40) | GSK3BMAPTTP53RAB9AGAA | |
| SCHEMBL5225757 | 0.82 | ITGB2 (0.50) | GSK3BMAPTTP53THRBRAB9A | |
| SCHEMBL9830752 | 0.64 | MAOA (0.44) | GSK3BTP53RAB9AALDH1A1TSHR | |
| SCHEMBL10808729 | 0.63 | GSK3B (0.41) | GSK3BMAPTTP53RAB9AALDH1A1 | |
| SCHEMBL7289212 | 0.63 | MAOA (0.47) | GSK3BMAPTTP53RAB9AALDH1A1 | |
| SCHEMBL1451143 | 0.62 | MAOA (0.50) | MAPTTP53RAB9AALDH1A1HPGD | |
| SCHEMBL10803547 | 0.61 | MAOA (0.42) | GSK3BRAB9AALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL10675503 | 0.61 | MAOA (0.48) | GSK3BMAPTTP53RAB9AALDH1A1 | |
| SCHEMBL10352937 | 0.61 | MAOA (0.44) | GSK3BMAPTTP53RAB9AALDH1A1 | |
| SCHEMBL27686338 | 0.61 | CHRNA7 (0.47) | MAPTALDH1A1HPGDTSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006503862-A | — | — | 2006-02-02 | — | — | JP | claimed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | claimed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | claimed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | GSK3B 428/4885MAPT 24/4885TP53 4478/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | GSK3B 26/4885MAPT 24/4885TP53 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.